Retraction notice to "Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: Relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells" [Biochim. Biophys. Acta 1689 (2004) 267-272];Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: Relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1689, Issue 3, 2004, Pages 267-272

  Kato, Tetsuya ^a   Hashikabe, Hiroko ^a   Iwata, Chigusa ^a   Akimoto, Kazumi ^a   Hattori, Yoshiyuki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Actin cytoskeleton; Nitric oxide; Rho Rho kinase; Statin; Vascular smooth muscle

Indexed keywords

ACTIN; CYTOSKELETON PROTEIN; F ACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LIPOPOLYSACCHARIDE; MEVALONIC ACID; NITRIC OXIDE; PHALLACIDIN; RHO KINASE;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STRESS FIBER; VASCULAR SMOOTH MUSCLE;

EID: 3242766006     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.06.007     Document Type: Erratum

References (25)

1. Beasley D., Schwartz J.H., Brenner B.M. Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J. Clin. Invest. 87:1991;602-608
2. Busse R., Mulsch A. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells. FEBS Lett. 275:1990;87-90
3. Durante W., Schini V.B., Scott-Burden T., Junquero D.C., Kroll M.H., Vanhoutte P.M., Schafer A.I. Platelet inhibition by an L-arginine-derived substance released by IL-1 beta-treated vascular smooth muscle cells. Am. J. Phys. 261:1991;H2024-H2030
4. Kilbourn R.G., Griffith O.W. Overproduction of nitric oxide in cytokine-mediated and septic shock. J. Natl. Cancer Inst. 84:1992;827-831
5. Thiemermann C., Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur. J. Pharmacol. 182:1990;591-595
6. Behr D., Rupin A., Fabiani J.N., Verbeuren T.J. Distribution and prevalence of inducible nitric oxide synthase in atherosclerotic vessels of long-term cholesterol-fed rabbits. Atherosclerosis. 142:1999;335-344
7. Rupin A., Behr D., Verbeuren T.J. Increased activity of guanylate cyclase in the atherosclerotic rabbit aorta: role of non-endothelial nitric oxide synthases. Br. J. Pharmacol. 119:1996;1233-1238
8. Aji W., Ravalli S., Szabolcs M., Jiang X.C., Sciacca R.R., Michler R.E., Cannon P.J. L-Arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation. 95:1997;430-437
9. Shears L.L., Kawaharada N., Tzeng E., Billiar T.R., Watkins S.C., Kovesdi I., Lizonova A., Pham S.M. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J. Clin. Invest. 100:1997;2035-2042
10. Kibbe M., Billiar T., Tzeng E. Inducible nitric oxide synthase and vascular injury. Cardiovasc. Res. 43:1999;650-657
11. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333:1995;1301-1307
12. the Scandinavian Simvastatin Survival Study (4S), Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 344:1994;1383-1389
13. Takeuchi S., Kawashima S., Rikitake Y., Ueyama T., Inoue N., Hirata K., Yokoyama M. Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. Biochem. Biophys. Res. Commun. 269:2000;97-102
14. Laufs U., Marra D., Node K., Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J. Biol. Chem. 274:1999;21926-21931
15. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;265-272
16. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430
17. Casey P.J. Protein lipidation in cell signaling. Science. 268:1995;221-225
18. Hattori Y., Nakanishi N., Kasai K. Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc. Res. 54:2002;649-658
19. Hattori Y., Kasai K. Disruption of the actin cytoskeleton up-regulates iNOS expression in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 43:2004;209-213
20. Chamley-Campbell J., Campbell G.R., Ross R. The smooth muscle cell in culture. Physiol. Rev. 59:1979;1-61
21. Gross S.S., Levi R. Tetrahydrobiopterin synthesis: an absolute requirement for cytokine induced nitric oxide generation by vascular smooth muscle. J. Biol. Chem. 267:1992;25722-25729
22. Kaibuchi K., Kuroda S., Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu. Rev. Biochem. 68:1999;459-486
23. Sah V.P., Seasholtz T.M., Sagi S.A., Brown J.H. The role of Rho in G protein-coupled receptor signal transduction. Annu. Rev. Pharmacol. Toxicol. 40:2000;459-489
24. Muck W., Ochmann K., Mazzu A., Lettieri J. Biopharmaceutical profile of cerivastatin: a novel HMG-CoA reductase inhibitor. J. Int. Med. Res. 27:1999;107-114
25. Tse F.L., Jaffe J.M., Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J. Clin. Pharmacol. 32:1992;630-638